Previous close | 24.69 |
Open | 25.33 |
Bid | 24.51 x 100 |
Ask | 24.63 x 400 |
Day's range | 24.55 - 25.50 |
52-week range | 12.54 - 28.91 |
Volume | |
Avg. volume | 399,780 |
Market cap | 935.837M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.08 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 43.20 |
Comparison with Analyst Estimates and Strategic Developments
CAMBRIDGE, England & BOSTON, May 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.
CAMBRIDGE, England & BOSTON, April 24, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.